Why the study?
What is the optimal duration of anticoagulation for patients with venous thromboembolism, particularly for a first unprovoked VTE?
What is the optimal duration of anticoagulation for patients with venous thromboembolism, particularly for a first unprovoked VTE?
Decision-making for the duration of anticoagulation after a first unprovoked VTE remains challenging due to unreliable predictive scores and unclear evidence on reduced-dose anticoagulation.
Novel VTE anticoagulation finding may refine duration decisions; leaves open validation before practice change.
Venous thromboembolism (VTE) is a common, serious condition that requires anticoagulation for at least three months to prevent recurrence and long-term complications. After this initial period, the decision to continue or stop anticoagulation depends on the balance between the risk of recurrent VTE and the risk of bleeding. Established guidelines suggest short-term anticoagulation for VTE caused by transient factors and indefinite anticoagulation for recurrent or cancer-associated VTE. However, for a first unprovoked VTE, decision-making remains challenging. Current predictive scores for recurrence and bleeding are not sufficiently reliable, and the safety and efficacy of reduced-dose anticoagulation remain unclear. In the future, precision and patient-centred medicine may improve treatment decisions in this area.
No takes yet. Share an insight, caveat, or question.
Couturaud et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: